{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:42:08Z","timestamp":1790880128529,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Randomized clinical trials have demonstrated efficacy and safety of erenumab. The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world setting in French patients with migraine associated with extreme unmet needs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a one year-prospective real-word study with enrolment of all consecutive adult patients included in the FHU InovPain registry who participated in a compassionate erenumab use program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 144 patients included, 140 patients (82.1% female \/ mean age of 50.9\u2009\u00b1\u200911.4) received at least one dose of erenumab and were concerned by effectiveness and safety assessment. All patients had failed 11 oral preventive treatments. Most of them suffered from chronic migraine (88.6%) and presented a medication overuse (90.7%) at baseline. Thirty-eight (27.1%) discontinued treatment during the 12-month follow-up, with 22 (15.7%), 11 (7.9%) and 5 (3.6%) patients before 3, 6 or 9\u00a0months of treatment. The proportion of\u2009\u2265\u200950% responders at M3, M6, M9 and M12 was 74\/140 (52.9%), 69\/118 (58.5%), 61\/107 (57.0%) and 60\/102 (58.8%) respectively. At M3, the rate of reversion from chronic migraine to episodic migraine was 57.3% and the rate of transition from medication overuse to non-overuse was 46.5%. For monthly migraine days, the median (IQR) was 18.0 (13.0\u201326.0), 9.0 (5.0\u201317.0), 7.5 (5.0\u201314.0), 8.0 (5.0\u201312.5) and 8.0 (5.0\u201312.0) at M0, M3, M6, M9 and M12 respectively. For HIT-6 score, the median (IQR) was 68.0 (63.8\u201373.3), 60.0 (54.0\u201365.0), 60.0 (50.3\u201353.0), 59.0 (50.0\u201363.0) and 58.0 (50.0\u201362.9) at M0, M3, M6, M9 and M12 respectively. Fifty-three (37.9%) patients reported at least one of the following adverse events: cutaneous erythema and\/or pain at the injection site for 42 (30%) patients, constipation for 22 (15.7%) patients, muscle spasm for 2 (1.4%) patients, alopecia for one (0.7%) patient and blood pressure increase in one (0.7%) patient. There was no serious adverse event. One female patient became pregnant after 5\u00a0months of exposure to erenumab with a safe evolution after treatment discontinuation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This first French real-world study related to migraine prevention with CGRP-mAbs confirms effectiveness and safety of erenumab in patients with extreme unmet needs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01680-4","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T15:02:58Z","timestamp":1699455778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study"],"prefix":"10.1186","volume":"24","author":[{"given":"M.","family":"Lanteri-Minet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alchaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bozzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Duchene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. K.","family":"Van Obberghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Donnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350","journal-title":"Nat Rev Neurol"},{"key":"1680_CR2","doi-asserted-by":"publisher","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P (2023). Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024231159366.","DOI":"10.1177\/03331024231159366"},{"key":"1680_CR3","doi-asserted-by":"publisher","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023). Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia. https:\/\/doi.org\/10.1177\/03331024231152169.","DOI":"10.1177\/03331024231152169"},{"key":"1680_CR4","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:2280\u20132287","journal-title":"Lancet"},{"key":"1680_CR5","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:1030\u20131040","journal-title":"Lancet"},{"key":"1680_CR6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19:814\u2013825","journal-title":"Lancet Neurol"},{"key":"1680_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"2","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK et al (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2:597\u2013607","journal-title":"Lancet Neurol"},{"key":"1680_CR8","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP et al (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453\u20131457","journal-title":"Lancet"},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/cells12010143","volume":"12","author":"AR Pavelic","year":"2022","unstructured":"Pavelic AR, W\u00f6ber C, Riederer F, Zebenholzer K (2022) Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells 12:143","journal-title":"Cells"},{"key":"1680_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11916-022-01077-z","volume":"26","author":"AM Murray","year":"2022","unstructured":"Murray AM, Stern JI, Robertson CE, Chiang CC (2022) Real-world patient experience of CGRP-targeting therapy for migraine: a narrative review. Curr Pain Headache Rep 26:783\u2013794","journal-title":"Curr Pain Headache Rep"},{"issue":"24","key":"1680_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-023-01611-3","volume":"2023","author":"N Vandenbussche","year":"2023","unstructured":"Vandenbussche N, Pisarek K, Paemeleire K (2023) Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. J Headache Pain 2023(24):75","journal-title":"J Headache Pain"},{"key":"1680_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.14194","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 61:1351\u20131363","journal-title":"Headache"},{"key":"1680_CR13","doi-asserted-by":"publisher","first-page":"805334","DOI":"10.3389\/fneur.2021.805334","volume":"12","author":"J Schoenen","year":"2021","unstructured":"Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, G\u00e9rard P (2021) Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes. Front Neurol 12:805334","journal-title":"Front Neurol"},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","volume":"23","author":"CK Cullum","year":"2022","unstructured":"Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A et al (2022) Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain 23:61","journal-title":"J Headache Pain"},{"key":"1680_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","volume":"23","author":"AP Andreou","year":"2022","unstructured":"Andreou AP, Fuccaro M, Hill B, Murphy M, Caponnetto V, Kilner R et al (2022) Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis. J Headache Pain 23:139","journal-title":"J Headache Pain"},{"key":"1680_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2014.11.004","volume":"16","author":"DW Dodick","year":"2015","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK et al (2015) Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain 16:164\u2013175","journal-title":"J Pain"},{"key":"1680_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102420973994","volume":"41","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U et al (2021) Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hocanalysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia 41:6\u201316","journal-title":"Cephalalgia"},{"key":"1680_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425\u2013434","journal-title":"Lancet Neurol"},{"key":"1680_CR19","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:e2309\u2013e2320","journal-title":"Neurology"},{"key":"1680_CR20","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","volume":"16","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U (2023) A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals (Basel) 16:934","journal-title":"Pharmaceuticals (Basel)"},{"key":"1680_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-023-01637-7","volume":"24","author":"J Schoenen","year":"2023","unstructured":"Schoenen J, Van Dycke A, Versijpt J, Paemeleire K (2023) Ten open questions in migraine prophylaxis\u00a0with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review. J Headache Pain 24:99","journal-title":"J Headache Pain"},{"key":"1680_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s10194-022-01470-4","volume":"23","author":"C Lampl","year":"2022","unstructured":"Lampl C, Kraus V, Lehner K, Loop B, Chehrenama M, Maczynska Z et al (2022) Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials. J Headache Pain 23:104","journal-title":"J Headache Pain"},{"key":"1680_CR23","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ et al (2019) Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39:1798\u20131808","journal-title":"Cephalalgia"},{"key":"1680_CR24","doi-asserted-by":"publisher","first-page":"e1897","DOI":"10.1212\/WNL.0000000000201008","volume":"99","author":"LS de Vries","year":"2022","unstructured":"de Vries LS, van der Arend BWH, Maassen VanDenBrink A, Terwindt GM (2022) Blood pressure in patients with migraine treated with monoclonal anti-CGRP (Receptor) antibodies: a prospective follow-up study. Neurology 99:e1897\u2013e1904","journal-title":"Neurology"},{"key":"1680_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/0333102420983292","volume":"41","author":"R Noseda","year":"2021","unstructured":"Noseda R, Bedussi F, Gobbi C, Zecca C, Ceschi A (2021) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia 41:789\u2013798","journal-title":"Cephalalgia"},{"key":"1680_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23:67","journal-title":"J Headache Pain"},{"key":"1680_CR27","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/0333102418801579","volume":"39","author":"P Vo","year":"2019","unstructured":"Vo P, Wen S, Martel MJ, Mitsikostas D, Reuter U, Klatt J (2019) Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia 39:608\u2013616","journal-title":"Cephalalgia"},{"key":"1680_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"2","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 2:76","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01680-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T15:03:00Z","timestamp":1699455780000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01680-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01680-4","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study did not require the authorization of an ethics committee. This study was part of the FHU InovPain database clinical research program which received authorization from the National Commission on Informatics and Liberty (<i>Commission Nationale de information et des Libert\u00e9s\u2014CNIL<\/i> \/ CIL register no. 278 dated 11\/09\/2017). Patients were included only after signing two separate written informed consents: the first enabling their personal data to be transmitted to Novartis Pharma SAS for validation of their eligibility in the compassionate program allowing them to benefit from free erenumab, and the second allowing the data collected in the FHU InovPain database to be used for clinical research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LMM received personal fees for consultancy activities from: Abbvie\/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer, Teva.FR had no conflict of interest.MC received personnal fees for consultancy activities from Lilly, LundbeckPK received personal fees for consultancy activities from Eli Lilly and LundbeckAH received personal fees for consultancy activities from Eli Lilly and NovartisBE had received personal fees for consultancy activities from AbbvieDML had no confict of interestsVOE had received personal fees for consultancy activities from AbbvieDA received personal fees for consultancy activities from Abbvie\/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer, TevaFD had no conlict of interest.FHU InvoPain received research support from Eli-Lilly, Lundbeck, Novartis, Pfizer and Teva.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}